Article: FOSAMAX Continues to Help Build Bone Through 10 Years of Treatment, Study in New England Journal of Medicine Finds.

Business Editors/Health/Medical Writers

UPPER GWYNEDD, Pa.--(BUSINESS WIRE)--March 17, 2004

Longest Prospective Clinical Trial in the Treatment of Postmenopausal

Osteoporosis Shows FOSAMAX(R) Maintained Bone Mineral Density at All

Skeletal Sites Measured

In the longest prospective clinical trial ever conducted in the treatment of postmenopausal osteoporosis -- a chronic condition that can lead to bone loss and susceptibility to fractures -- researchers found that postmenopausal women taking FOSAMAX(R) (alendronate sodium) maintained or continued to experience increases in bone mineral density (BMD) at the hip and spine ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!